title: NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
abstract: These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.
authors.affiliation: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
authors.forename: David S
authors.initials: DS
authors.lastname: Ettinger
authors.affiliation: University of Washington/Seattle Cancer Care Alliance
authors.forename: Douglas E
authors.initials: DE
authors.lastname: Wood
authors.affiliation: Huntsman Cancer Institute at the University of Utah
authors.forename: Wallace
authors.initials: W
authors.lastname: Akerley
authors.affiliation: UC San Diego Moores Cancer Center
authors.forename: Lyudmila A
authors.initials: LA
authors.lastname: Bazhenova
authors.affiliation: Fox Chase Cancer Center
authors.forename: Hossein
authors.initials: H
authors.lastname: Borghaei
authors.affiliation: University of Colorado Cancer Center
authors.forename: David Ross
authors.initials: DR
authors.lastname: Camidge
authors.affiliation: Roswell Park Cancer Institute
authors.forename: Richard T
authors.initials: RT
authors.lastname: Cheney
authors.affiliation: Dana-Farber/Brigham and Women’s Cancer Center
authors.forename: Lucian R
authors.initials: LR
authors.lastname: Chirieac
authors.affiliation: Duke Cancer Institute
authors.forename: Thomas A
authors.initials: TA
authors.lastname: D'Amico
authors.affiliation: Moffitt Cancer Center
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Dilling
authors.affiliation: University of Alabama at Birmingham Comprehensive Cancer Center
authors.forename: M Chris
authors.initials: MC
authors.lastname: Dobelbower
authors.affiliation: Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
authors.forename: Ramaswamy
authors.initials: R
authors.lastname: Govindan
authors.affiliation: Roswell Park Cancer Institute
authors.forename: Mark
authors.initials: M
authors.lastname: Hennon
authors.affiliation: Vanderbilt-Ingram Cancer Center
authors.forename: Leora
authors.initials: L
authors.lastname: Horn
authors.affiliation: UCSF Helen Diller Family Comprehensive Cancer Center
authors.forename: Thierry M
authors.initials: TM
authors.lastname: Jahan
authors.affiliation: The University of Texas MD Anderson Cancer Center
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Komaki
authors.affiliation: Fred & Pamela Buffett Cancer Center
authors.forename: Rudy P
authors.initials: RP
authors.lastname: Lackner
authors.affiliation: Massachusetts General Hospital Cancer Center
authors.forename: Michael
authors.initials: M
authors.lastname: Lanuti
authors.affiliation: Yale Cancer Center/Smilow Cancer Hospital
authors.forename: Rogerio
authors.initials: R
authors.lastname: Lilenbaum
authors.affiliation: University of Michigan Comprehensive Cancer Center
authors.forename: Jules
authors.initials: J
authors.lastname: Lin
authors.affiliation: The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute
authors.forename: Billy W
authors.initials: BW
authors.lastname: Loo
authors.affiliation: Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
authors.forename: Renato
authors.initials: R
authors.lastname: Martins
authors.affiliation: The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Otterson
authors.affiliation: Robert H. Lurie Comprehensive Cancer Center of Northwestern University
authors.forename: Jyoti D
authors.initials: JD
authors.lastname: Patel
authors.affiliation: The University of Texas MD Anderson Cancer Center
authors.forename: Katherine M
authors.initials: KM
authors.lastname: Pisters
authors.affiliation: City of Hope Comprehensive Cancer Center
authors.forename: Karen
authors.initials: K
authors.lastname: Reckamp
authors.affiliation: Memorial Sloan Kettering Cancer Center
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Riely
authors.affiliation: Mayo Clinic Cancer Center
authors.forename: Steven E
authors.initials: SE
authors.lastname: Schild
authors.affiliation: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
authors.forename: Theresa A
authors.initials: TA
authors.lastname: Shapiro
authors.affiliation: Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
authors.forename: Neelesh
authors.initials: N
authors.lastname: Sharma
authors.affiliation: Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
authors.forename: James
authors.initials: J
authors.lastname: Stevenson
authors.affiliation: Dana-Farber/Brigham and Women’s Cancer Center
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Swanson
authors.affiliation: St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center
authors.forename: Kurt
authors.initials: K
authors.lastname: Tauer
authors.affiliation: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Yang
authors.affiliation: National Comprehensive Cancer Network
authors.forename: Kristina
authors.initials: K
authors.lastname: Gregory
authors.affiliation: National Comprehensive Cancer Network
authors.forename: Miranda
authors.initials: M
authors.lastname: Hughes
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D000077143:Docetaxel; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077594:Nivolumab; D017410:Practice Guidelines as Topic; D015996:Survival Rate; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D043823:Taxoids; D000077143:Docetaxel; D000077594:Nivolumab; C582435:pembrolizumab